News from sutro biopharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 22, 2020, 07:00 ET Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...


Jun 09, 2020, 07:00 ET Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...


May 21, 2020, 07:15 ET Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...


May 21, 2020, 07:00 ET Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards-- Carlos Paya, MD, PhD, and Lainie Martin, MD

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...


May 14, 2020, 16:01 ET Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary...


May 11, 2020, 23:55 ET Sutro Biopharma Announces Pricing of $85.3 Million Public Offering

Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary...


May 11, 2020, 16:15 ET Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and Developments

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...


May 11, 2020, 16:01 ET Sutro Biopharma Announces Proposed Public Offering

Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary...


Apr 27, 2020, 00:01 ET Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...


Apr 20, 2020, 16:35 ET Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...


Apr 13, 2020, 17:00 ET Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020

Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that the company has been invited to present updated clinical data from its STRO-002...


Mar 16, 2020, 07:00 ET Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...


Mar 12, 2020, 07:00 ET Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...


Mar 04, 2020, 07:00 ET Sutro Biopharma to Present Innovative Cancer Therapy Approach Using Precise Tumor Targeted Immunostimulants at World ADC London

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...


Feb 27, 2020, 07:00 ET Sutro Biopharma to Present at the Cowen and Company 40th Annual Health Care Conference

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...


Feb 05, 2020, 07:30 ET Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...


Jan 09, 2020, 07:00 ET Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...


Jan 08, 2020, 09:26 ET Sutro Biopharma Appoints James Panek to Board of Directors

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...


Jan 03, 2019, 16:05 ET Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference

Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 37th Annual J.P. Morgan...


Oct 12, 2018, 07:00 ET Sutro's STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

Sutro Biopharma, Inc. (NASDAQ: STRO), has been granted Orphan Drug Designation by the United States Food and Drug Administration (FDA) for STRO-001...


Jul 26, 2018, 10:45 ET Sutro Biopharma Announces $85.4 Million Series E Round

Sutro Biopharma, Inc., has secured $85.4 million in Series E financing to advance its wholly-owned pipeline of novel cancer therapeutics, including...


Jul 24, 2018, 08:00 ET Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders

Sutro Biopharma, Inc., has signed a collaboration and licensing agreement with Merck, known as MSD outside the United States and Canada, to discover...


Apr 26, 2018, 08:00 ET Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment; The First of a New Generation of Precisely Engineered ADCs

Sutro Biopharma, Inc. has begun dosing patients in its initial clinical trial of its potential first-in-class antibody drug conjugate, or ADC,...


Apr 16, 2018, 06:30 ET Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research

Sutro Biopharma's first antibody drug conjugate (ADC) to treat solid tumors was highly effective against ovarian cancer in preclinical xenograft...


Dec 12, 2017, 07:00 ET Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple Myeloma Preclinical Studies

Two studies presented yesterday at the American Society of Hematology's annual meeting in Atlanta showed frequent expression of CD74, a cell-surface...